Avid Bioservices (CDMO) Craig-Hallum Bioprocessing Virtual Conference summary

Industry positioning and evolution

• Focuses on the 'make it' phase of drug development, specializing in process development and manufacturing for biopharmaceuticals, serving small to large biotech and pharma clients.

• Emphasizes the importance of robust, reliable, and regulated processes due to the complexity of biological systems and regulatory requirements.

• Industry has shifted from an art to a science, with significant gains in productivity and predictability over the past 40 years.

• Adoption of single-use systems has improved environmental sustainability, operational flexibility, and reduced contamination risks.

• Regulatory harmonization through ICH guidelines has made global operations more predictable.

Manufacturing process and technological advancements

• Manufacturing starts with cell line development, using cells as mini factories to produce therapeutic proteins.

• Scale-up involves cell culturing and production in bioreactors, with a current industry sweet spot at 2,000 L disposable bioreactors.

• Purification uses filtration, centrifugation, and chromatographic techniques to isolate the drug substance.

• Single-use technology streamlines changeovers, enhances safety, and simplifies regulatory inspections.

• Advances in process intensification and cell density have dramatically increased yields and reduced cycle times.

Market trends and strategic focus

• Biologics now represent nearly 50% of pharma sales, with gene therapy as the next frontier.

• Biopharmaceuticals are seen as more compatible with the human body and less toxic than small molecules.

• Growth potential remains high, as only 25% of new molecular entities approved between 2010-2020 were biopharmaceuticals.

• Personalized medicine and rare disease treatments are driving demand for smaller, more productive bioreactors.

• U.S. market and location in Southern California are considered strategic advantages.